The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions.

The recent resolution of semaglutide and tirzepatide shortages by the US Food and Drug Administration (FDA) has fundamentally altered the regulatory landscape for compounded obesity medications. Despite recent federal pricing agreements to reduce GLP-1 costs, ongoing affordability barriers continue to drive patient desperation, fueling a shift toward unsupervised strategies such as "microdosing" and the purchase of illicit "research-grade" peptides from online sources and unregulated providers including medical spas. This brief report addresses critical gaps for nurse practitioners (NPs): the drivers behind subtherapeutic microdosing (specifically gastrointestinal tolerability and "vanity weight"); the specific side effects and dosing errors encountered with these practices; the safety risks associated with pen manipulation, compounded vials, and medication sharing; and the legal pitfalls surrounding compounded "copies." The role of provider weight bias as a driver of patients toward unregulated alternatives is examined, with practical strategies for NPs to mitigate stigma in clinical encounters. As the regulatory window closes on mass compounding, NPs must guide patients away from hazardous false economies, develop approaches for managing patients already using compounded products, and recognize the narrow role for legitimate compounding in patients with documented allergies.